MetLife reports Q2 results today with options traders showing the most defensive positioning in weeks — even as the analyst community remains uniformly bullish.
The clearest signal heading into the print is in options. The put/call ratio jumped to 1.31 on August 5, more than two standard deviations above its 20-day average of 1.20. That's the most elevated defensive reading in roughly a month, suggesting investors are paying up for downside protection on the day of the release. The move is notable because the stock itself has been calm — MET closed at $96.26, up just 0.1% on the day and 6.9% higher than a month ago. Short interest, at 2.1% of the free float, is a non-story: borrowing costs remain near rock-bottom at 0.41%, and availability is extraordinarily loose, with 407 million shares available to borrow against roughly 14 million shorted. There is no squeeze pressure here, and no meaningful bearish conviction in the lending market.
The analyst story is unchanged from the preview published four days ago: every recent action has been a target raise, with no downgrades. JP Morgan and TD Cowen each lifted targets into the $105–$106 range, and Morgan Stanley moved its target up $10 to $103. The consensus mean of $97.75 now sits essentially at parity with the current price, meaning the re-rating that made MET look cheap has largely run its course. Bulls point to the forward growth profile — 12-month EPS momentum ranks in the 93rd percentile, and the five-year EBIT CAGR runs near 30%. Bears note that the stock's history of beating estimates is patchy, with EPS surprise ranking only in the 36th percentile. One prior earnings reaction in the dataset showed MET dipping roughly 2% on the day before recovering to near-flat over five sessions.
Among insurance peers, MET has held steadier than most over the past week. LNC surged nearly 10% on the week after its own results. PRU and AIG both slipped. MET's flat-to-slightly-lower weekly performance (-0.8%) puts it in the middle of the peer pack — consistent with a stock that has already re-rated and where the market is waiting for the print to validate the move.
Today's release tests whether MetLife's underlying Q2 earnings quality justifies a valuation that, at a forward PE near 9.1x and price-to-book of 1.98x, now fully reflects the Street's refreshed optimism.
See the live data behind this article on ORTEX.
Open MET on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
